Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
NCT00067080
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
195
Enrollment
INDUSTRY
Sponsor class
Conditions
Anemia, Sickle Cell
Interventions
DRUG:
ICL670, deferoxamine
Sponsor
Novartis Pharmaceuticals